- Home
- TGB vs MESO Comparison
TGB vs MESO Comparison
Compare TGB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGB | MESO |
|---|---|---|
| Founded | 1966 | 2004 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TGB | MESO |
|---|---|---|
| Price | $6.08 | $19.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 6.1M | 218.4K |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $428,559,326.00 | $17,198,000.00 |
| Revenue This Year | $10.35 | $576.59 |
| Revenue Next Year | $61.39 | $41.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.50 | ★ 191.39 |
| 52 Week Low | $1.67 | $9.61 |
| 52 Week High | $6.32 | $21.00 |
Technical Indicators
Market Signals| Indicator | TGB | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 68.90 | 60.87 |
| Support Level | $5.49 | $17.90 |
| Resistance Level | $6.32 | $18.73 |
| Average True Range (ATR) | 0.23 | 0.56 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 80.33 | 70.00 |
Price Performance
Historical ComparisonAbout TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.